Nodofree Combi (Dorzolamide Hydrochloride, Timolol Maleate)

Dorzolamide Hydrochloride and Timolol Maleate, the active ingredients in Nodofree Combi, are a carbonic anhydrase inhibitor and a non‑selective β‑adrenergic antagonist presented as an ophthalmic eye‑drop solution for ocular use. The combination lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Nodofree Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Nodofree Combi is employed in the management of ocular conditions that require a sustained reduction of intra‑ocular pressure, thereby protecting optic nerve health.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure, helping to preserve visual field and reduce optic nerve damage. - Ocular hypertension: reduces elevated eye pressure, decreasing the risk of developing glaucoma over time. - Secondary glaucoma (e.g., pigmentary or pseudoexfoliative): assists in pressure control when used as adjunct therapy.

Eye‑drop therapy with Nodofree Combi may be associated with local and systemic adverse reactions.

Common Side Effects: - Transient ocular burning or stinging upon instillation. - Temporary blurred vision. - Conjunctival hyperemia (redness). - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction such as angio‑edema or anaphylaxis. - Persistent low heart rate or bronchospasm. - Significant visual loss or corneal ulceration.

Before prescribing Nodofree Combi, clinicians should consider several safety precautions to minimize risks.

- Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. - Evaluate respiratory health: use cautiously in asthma or chronic obstructive pulmonary disease. - Monitor for sulfonamide allergy: dorzolamide contains a sulfonamide moiety. - Check intra‑ocular pressure response: adjust therapy if target pressure not achieved. - Avoid concurrent use with other β‑blocker eye drops: may increase systemic absorption. - Store at below 25 °C: keep in the original container, protect from light and moisture.

Nodofree Combi can interact with systemic and ocular medications, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent oral β‑blockers: may cause additive bradycardia or hypotension. - Non‑selective β‑blocker inhalers (e.g., albuterol): may reduce bronchodilator effectiveness. - MAO inhibitors: increased risk of hypertensive crisis when combined with timolol.

Moderate Interactions (Monitor Closely): - Other carbonic anhydrase inhibitors: may enhance ocular irritation. - Anticholinergic eye drops: could affect pupil size and intra‑ocular pressure control. - Systemic diuretics: monitor electrolyte balance and blood pressure.